Please login to the form below

Not currently logged in
Email:
Password:

Bayer to pay minimum of $110m to settle birth control lawsuits

German pharma company resolves 500 claims that Yasmin and Yaz contraceptive products caused blood clots

Bayer will face a minimum settlement charge of $110m to resolve 500 lawsuits over the safety of its Yaz family of birth control drugs.

As reported by Bloomberg, the Germany-based pharma company has agreed to pay an average of $220,000 per case to settle claims its Yasmin and Yaz contraceptive products led to blood clots.

Bloomberg's sources have requested to remain anonymous.

Bayer had been accused of misleading the public about the health risks of its products, with safety reviews suggesting that drospirenone-containing birth control pills, such as Yasmin and Yaz, may be more likely to cause venous thromboembolism (VTE), potentially leading to incidents of stroke and heart attack.

This led to the US Food and Drug Administration's (FDA) decision to revise the labels of drospirenone products to warn of the increased risk.

“Bayer HealthCare confirms that some cases pending in the current YAZ/Yasmin litigation in the US are being settled,” said Rosemarie Yancosek, a spokesperson for Bayer.

Bayer is currently facing more than 11,000 lawsuits in the US alleging injury caused by use of Yaz or Yasmin oral contraceptives or authorised generic equivalents.

If the remaining 10,500+ lawsuits match the average £220,000 figure for each of the first 500 cases, Bayer would have to pay out well over $2bn.

This would be more than double Johnson and Johnson's (J&J) $1.1bn fine in Arkansas after the healthcare giant was found to have misled and hid risks of its antipsychotic Risperdal (risperidone) in its marketing.

The Yaz family of products is one of Bayer's biggest sellers, making revenues of $1.1bn during 2011, although this was down on 2010's figures.

16th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics